深圳北芯生命科技股份有限公司董事长、总经理（首席执行官）宋亮先生致辞

Core Insights - The company, Shenzhen Beixin Life Technology Co., Ltd., has successfully completed its initial public offering and is now listed on the Sci-Tech Innovation Board, marking a significant milestone in its growth journey [2] - The company focuses on innovative and high-quality solutions for cardiovascular disease treatment, emphasizing its commitment to clinical and patient-centered approaches [2] Product Development - The core products, including the Intravascular Ultrasound (IVUS) system and the Fractional Flow Reserve (FFR) system, have entered the national special review process for innovative medical devices, which is expected to transform clinical practices in Percutaneous Coronary Intervention (PCI) [3] - The Pulsed Field Ablation (PFA) system for atrial fibrillation treatment is also in the special review process and is the first PFA product from China to be included in the late-breaking clinical trial at the European Society of Cardiology Congress [3] - The InsightPFA clinical research results have been published in the top cardiovascular journal, JACC, representing the first randomized controlled clinical study of nanosecond pulse PFA in the industry [3] Future Outlook - The medical device sector is entering a new cycle of innovation characterized by intelligence and precision, presenting a historic strategic opportunity for Chinese medical enterprises to develop into globally influential medical technology companies over the next decade [4] - The company aims to leverage the "Healthy China" strategy, maintaining its focus on cardiovascular precision intervention and striving for exceptional quality, thereby showcasing the strength of Chinese innovation to the world [4] - The company expresses a desire for investors to understand its value proposition and growth potential, highlighting the opportunity for shared long-term growth [4]